In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
German pharma major Bayer has secured a positive reimbursement decision from the UK’s health technology assessor for Nubeqa (darolutamide). 19 May 2023
Generics
The US Food and Drug Administration has published product-specific guidance for generics drugmakers with the goal of facilitating pipeline development and promoting access. 19 May 2023
Pharmaceutical
An Expert View from George Magrath, an ophthalmologist and chief executive of USA-based biopharma company Lexitas. 19 May 2023
Biotechnology
French pharma major Sanofi has successfully completed the Phase I trial for its von Willebrand disease (vWD) therapy, efanesoctocog alfa (BIV001), a novel antihemophilic factor recombinant fusion protein that acts as a coagulation factor VIII therapy. 19 May 2023
Generics
Famed as a great success story of the generics sector in previous decades, Israel’s Teva Pharmaceutical Industries has seen its growth and share price tail off since the mid-2010s. 18 May 2023
Pharmaceutical
As part of its ongoing inquiry into pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the USA’s Federal Trade Commission (FTC) has issued compulsory orders to two group purchasing organizations (GPOs) that negotiate drug rebates on behalf of other PBMs. 18 May 2023
Biotechnology
The US Food and Drug Administration (FDA) has eased the partial clinical hold on AOC 1001, allowing Avidity Biosciences, the drug’s developer, to double the number of participants in the MARINA Open-Label Extension (MARINA-OLE) study receiving 4 mg/kg of AOC 1001. 18 May 2023
Pharmaceutical
New guidance has been developed by the European Medicines Agency to help the pharmaceutical industry maintain continuity of supply and prevent shortages. 18 May 2023
Pharmaceutical
CSL Vifor, the iron deficiency and nephrology specialist owned by Australia’s CSL, has announced an update from the UK. 18 May 2023
Pharmaceutical
Today’s announcement that the UK’s National Institute for Health and Care Excellence (NICE) has published Final Draft Guidance (FDG) recommending dapagliflozin for adult patients with symptomatic chronic heart failure (HF) with preserved or mildly reduced ejection fraction (LVEF of more than 40%) in England and Wales is a significant day for patients and the wider cardiology community. 18 May 2023
Biotechnology
UK-based Senisca, a biotech company developing RNA-based therapeutics to reverse cellular senescence and target age-related disease, has announced an expansion of its leadership team. 18 May 2023
Pharmaceutical
USA-based ophthalmic diseases specialist EyePoint Pharmaceuticals saw its share leap 15.4% to $7.40 in pre-market trading today, as it announced a definitive agreement for the sale of Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences. 18 May 2023
Pharmaceutical
Shares of US drug developer Intercept Pharmaceuticals closed down 14.7% at $13.83 yesterday, after the US Food and Drug Administration released briefing document ahead of the FDA’s Gastrointestinal Drugs Advisory Committee. 18 May 2023
Biotechnology
Positive results from the Phase III APHENITY study have lifted shares in PTC Therapeutics by around 8%. 18 May 2023
Biotechnology
US biotech Novavax’ COVID-influenza combination (CIC) vaccine reflects a wider industry trend for increased usage of artificial intelligence (AI) in clinical trial design, says data and analytics company GlobalData. 18 May 2023
Pharmaceutical
A feature on the US drugmaker's drive to replace declining sales of the world's biggest-selling drug. 18 May 2023
Biotechnology
Not-for-profit UK medical research organization LifeArc and techbio company PrecisionLife have announced a strategic R&D collaboration to accelerate the discovery and development of targeted treatments for amyotrophic lateral sclerosis (ALS), a disease also known as motor neurone disease. 17 May 2023
Biotechnology
Shares in Australian immunotherapy specialist Immutep are up 15% after news of a positive clinical trial result in lung cancer. 17 May 2023
Biotechnology
Californian genetic medicine company Scribe Therapeutics has lined up another deal with a pharma major to out-license its technologies. 17 May 2023
Biotechnology
The US Food and Drug Administration (FDA) has accepted Japanese pharma major Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficiency disorder, for priority review. 17 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze